Five numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
the abstract, start to end
… (IQR 12-52), Evolocumab reduced LDL-c by -61.09% (95% CI: -64.81, -57.38, p<0.01) and Alirocumab reduced LDL-c by -46.35% (95% CI: -51.75, -41.13, …
Inclisiran 284mg reduced LDL-c by -54.83% (95% CI: -59.04, -50.62, p = 0.05) and Inclisiran 300mg reduced LDL-c by -43.11% (95% CI: -52.42, -33.80, p = …
… risk of myocardial infarction (MI), OR 0.72 (95% CI: 0.64, 0.81, p<0.01), …
← favours treatmentfavours comparator →
could be chanceLipids
−61.09−64.8 to −57.4
Lipids
−46.35−51.8 to −41.1
Lipids
−54.83−59.0 to −50.6
Lipids
−43.11−52.4 to −33.8
Cardiovascular events
OR 0.720.64–0.81
PCSK9 inhibitorsLipidsCardiovascular events
PCSK9 inhibitors × lipidshelps?settled
unlikelylikely
0.93not counted
← favours treatmentfavours comparator →
1 / 5